222 selected records with a cited source date in 2013, shown 200 per page, newest first. This archive is selective and does not imply continuous monitoring or complete historical coverage.
PeptideScanner retained ClinicalTrials.gov record NCT00475852 at 2026-11-16T01:39:41.882Z. Its registry update date was 2013-03-08, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT00597584 at 2026-11-16T17:45:11.119Z. Its registry update date was 2013-03-08, and PeptideScanner's reviewed identity mapping was peginesatide.
The Federal Register published notice 2013-04827, attributed to FDA and its parent HHS department, on 2013-03-04. Its official title is “Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Sermorelin.
PeptideScanner retained ClinicalTrials.gov record NCT01561066 at 2026-07-30T21:55:56.621Z. Its registry update date was 2013-02-26, and PeptideScanner's reviewed identity mapping was octreotide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 200219 with status AP dated 2013-02-13, and names oxytocin among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT00597753 at 2026-11-16T17:45:11.119Z. Its registry update date was 2013-02-12, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT00598273 at 2026-11-16T17:45:11.119Z. Its registry update date was 2013-02-12, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT00598442 at 2026-11-16T17:45:11.119Z. Its registry update date was 2013-02-12, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT01071915 at 2026-11-15T21:52:09.579Z. Its registry update date was 2013-02-12, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT01700478 at 2026-11-15T22:08:31.832Z. Its registry update date was 2013-02-11, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00061373 at 2026-11-15T21:59:29.646Z. Its registry update date was 2013-02-04, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained PubMed bibliographic metadata for PMID 22840755 at 2026-07-30T21:57:01.388Z. PubMed recorded a metadata revision date of 2013-02-01 and an Entrez history date of 2012-07-31. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT00730015 at 2026-07-30T21:55:56.622Z. Its registry update date was 2013-01-30, and PeptideScanner's reviewed identity mapping was linaclotide.
PubMed lists PMID 23356276 in Biochemical Society transactions as Journal Article, Research Support, N.I.H., Extramural, Review, with publication-date metadata of 2013-02-01 (day precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The official Drugs@FDA dataset lists original submission 1 for ANDA 091280 with status AP dated 2013-01-25, and names desmopressin acetate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT00738673 at 2026-11-15T21:52:09.579Z. Its registry update date was 2013-01-18, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained PubMed bibliographic metadata for PMID 23078121 at 2026-07-30T21:57:01.393Z. PubMed recorded a metadata revision date of 2013-01-16 and an Entrez history date of 2012-10-20. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.
The Federal Register published notice 2013-00507, attributed to FDA and its parent HHS department, on 2013-01-14. Its official title is “Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.
PeptideScanner retained ClinicalTrials.gov record NCT01430104 at 2026-07-30T21:55:56.620Z. Its registry update date was 2013-01-14, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01764230 at 2026-11-15T21:49:16.513Z. Its registry update date was 2013-01-09, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00967018 at 2026-11-15T21:52:09.579Z. Its registry update date was 2013-01-03, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained PubMed bibliographic metadata for PMID 23140265 at 2026-07-30T21:57:01.395Z. PubMed recorded a metadata revision date of 2013-01-01 and an Entrez history date of 2012-11-13. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.